Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence

Roger S McIntyre1,2,3,4, Jinju Yoon3, Jeanette M Jerrell5, Samantha S Liauw31Department of Psychiatry, University of Toronto, Toronto, ON, Canada; 2Department of Pharmacology, University of Toronto, Toronto, ON, Canada; 3Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	McIntyre R, Yoon J, Jerrell JM, Liauw SS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/7d015d8b46b6441ba086243db7495034
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7d015d8b46b6441ba086243db7495034
record_format	dspace
spelling	oai:doaj.org-article:7d015d8b46b6441ba086243db74950342021-12-02T00:36:51ZAripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence1176-63281178-2021https://doaj.org/article/7d015d8b46b6441ba086243db74950342011-05-01T00:00:00Zhttp://www.dovepress.com/aripiprazole-for-the-maintenance-treatment-of-bipolar-disorder-a-revie-a7532https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Roger S McIntyre1,2,3,4, Jinju Yoon3, Jeanette M Jerrell5, Samantha S Liauw31Department of Psychiatry, University of Toronto, Toronto, ON, Canada; 2Department of Pharmacology, University of Toronto, Toronto, ON, Canada; 3Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; 4Institute of Medical Science, University of Toronto, Toronto, ON, Canada; 5Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, Columbia, SC, USAAbstract: We aimed to review and synthesize results reporting on the maintenance efficacy of Aripiprazole in adults with bipolar I disorder. Aripiprazole is FDA approved for the acute and maintenance treatment of bipolar I disorder. Aripiprazole&#39;s efficacy during the long-term treatment of bipolar disorder is supported by extension of acute phase studies and long-term (ie, 100-week) double-blind placebo controlled recurrence prevention registration trials. Aripiprazole is not established as efficacious in the acute or maintenance treatment of bipolar depression. Moreover, aripiprazole&#39;s efficacy during the acute or maintenance phase of bipolar II disorder has not been sufficiently studied. Aripiprazole has a relatively lower hazard for metabolic disruption and change in body composition when compared to other atypical agents (eg, olanzapine, quetiapine). Moreover, aripiprazole has minimal propensity for sedation, somnolence and prolactin elevation. Aripiprazole is associated with extrapyramidal side effects, notably akathisia, which in most cases is not severe or treatment limiting. Future research vistas are to explore aripiprazole&#39;s efficacy in bipolar subgroups; recurrence prevention of bipolar depression; and in combination with other mood stabilizing agents.Keywords: aripiprazole, bipolar disorder, maintenance, pharmacologyMcIntyre RYoon JJerrell JMLiauw SSDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 319-323 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 McIntyre R Yoon J Jerrell JM Liauw SS Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
description	Roger S McIntyre1,2,3,4, Jinju Yoon3, Jeanette M Jerrell5, Samantha S Liauw31Department of Psychiatry, University of Toronto, Toronto, ON, Canada; 2Department of Pharmacology, University of Toronto, Toronto, ON, Canada; 3Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; 4Institute of Medical Science, University of Toronto, Toronto, ON, Canada; 5Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, Columbia, SC, USAAbstract: We aimed to review and synthesize results reporting on the maintenance efficacy of Aripiprazole in adults with bipolar I disorder. Aripiprazole is FDA approved for the acute and maintenance treatment of bipolar I disorder. Aripiprazole&#39;s efficacy during the long-term treatment of bipolar disorder is supported by extension of acute phase studies and long-term (ie, 100-week) double-blind placebo controlled recurrence prevention registration trials. Aripiprazole is not established as efficacious in the acute or maintenance treatment of bipolar depression. Moreover, aripiprazole&#39;s efficacy during the acute or maintenance phase of bipolar II disorder has not been sufficiently studied. Aripiprazole has a relatively lower hazard for metabolic disruption and change in body composition when compared to other atypical agents (eg, olanzapine, quetiapine). Moreover, aripiprazole has minimal propensity for sedation, somnolence and prolactin elevation. Aripiprazole is associated with extrapyramidal side effects, notably akathisia, which in most cases is not severe or treatment limiting. Future research vistas are to explore aripiprazole&#39;s efficacy in bipolar subgroups; recurrence prevention of bipolar depression; and in combination with other mood stabilizing agents.Keywords: aripiprazole, bipolar disorder, maintenance, pharmacology
format	article
author	McIntyre R Yoon J Jerrell JM Liauw SS
author_facet	McIntyre R Yoon J Jerrell JM Liauw SS
author_sort	McIntyre R
title	Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
title_short	Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
title_full	Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
title_fullStr	Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
title_full_unstemmed	Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
title_sort	aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/7d015d8b46b6441ba086243db7495034
work_keys_str_mv	AT mcintyrer aripiprazoleforthemaintenancetreatmentofbipolardisorderareviewofavailableevidence AT yoonj aripiprazoleforthemaintenancetreatmentofbipolardisorderareviewofavailableevidence AT jerrelljm aripiprazoleforthemaintenancetreatmentofbipolardisorderareviewofavailableevidence AT liauwss aripiprazoleforthemaintenancetreatmentofbipolardisorderareviewofavailableevidence
_version_	1718403627695996928

Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence

Ejemplares similares